Giazo

Giazo Uses, Dosage, Side Effects, Food Interaction and all others data.

Giazo is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK.

The chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt.

Giazo works by deliverying mesalazine to the large intestine to act directly on ulcerative colitis. Mesalazine is also known as 5-aminosalicylic acid, or 5-ASA.

Table Of contents

• Giazo
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Giazo
Availability	Prescription only
Generic	Balsalazide
Balsalazide Other Names	Balsalazida, Balsalazide, Balsalazidum
Related Drugs	Lialda, Pentasa, Apriso, Azulfidine, Asacol, Canasa, Delzicol, Asacol HD, Dipentum, Rowasa
Weight	750mg, 1.1g,
Type	Oral Capsule, Oral Tablet, Tablet, Film Coated
Formula	C17H15N3O6
Weight	Average: 357.3175 Monoisotopic: 357.096085227
Protein binding	≥99%
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Giazo is an aminosalicylate used to treat ulcerative colitis.

For the treatment of mildly to moderately active ulcerative colitis.

Giazo is also used to associated treatment for these conditions: Mild Ulcerative Colitis, Moderate Ulcerative colitis

How Giazo works

The mechanism of action of 5-aminosalicylic acid is unknown, but appears exert its anti-inflammatory effects locally (in the GI tract) rather than systemically. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (catalyzes the formation of prostaglandin precursors from arachidonic acid), and through the lipoxygenase pathways (catalyzes the formation of leukotrienes and hydroxyeicosatetraenoic acids from arachidonic acid and its metabolites), is increased in patients with chronic inflammatory bowel disease. Therefore, it is possible that 5-aminosalicylic acid diminishes inflammation by blocking production of arachidonic acid metabolites in the colon through both the inhibition of cyclooxygenase and lipoxygenase.

Toxicity

A single oral dose of balsalazide disodium at 5 grams/kg or 4-aminobenzoyl-(beta)-alanine, a metabolite of balsalazide disodium, at 1 gram/kg was non-lethal in mice and rats. No symptoms of acute toxicity were seen at these doses.

Food Interaction

• Take with or without food.

Giazo Drug Interaction

Unknown: zolpidem, zolpidem, aspirin, aspirin, duloxetine, duloxetine, omega-3 polyunsaturated fatty acids, omega-3 polyunsaturated fatty acids, adalimumab, adalimumab, metoprolol, metoprolol, acetaminophen, acetaminophen, cyanocobalamin, cyanocobalamin, ascorbic acid, ascorbic acid, cholecalciferol, cholecalciferol

Giazo Disease Interaction

Moderate: renal dysfunction

Elimination Route

Low and variable, intact balsalazide is poorly absorbed systemically.

Half Life

Half-life could not be determined.

Elimination Route

The products of the azoreduction of this compound, 5-ASA and 4-aminobenzoyl-ß-alanine, and their N-acetylated metabolites have been identified in plasma, urine and feces. Following single-dose administration of 2.25 g COLAZAL (three 750 mg capsules) under fasting conditions in healthy subjects, mean urinary recovery of balsalazide, 5-ASA, and N-Ac-5-ASA was 0.20%, 0.22% and 10.2%, respectively.

Innovators Monograph

You find simplified version here Giazo